FDA approves Dificid for oral suspension and for children aged 6 months and over to treat Clostridioides (formerly Clostridium) difficile-associated diarrhea.-Merck Inc.+ Astellas
Related news and insights
Summit Therapeutics Inc. announced topline results for the Phase III Ri-CoDIFy study evaluating its investigational drug, ridinilazole, for the treatment of and Sustained Clinical Response (SCR) for patients suffering from C. difficile infection (C. diff. infection or CDI).
Seres Therapeutics, Inc. announced that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER 109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic.